SecBot SecBot
PRESS-RELEASE ·Filed May 21, 2026

COAG

Hemab Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The IPO removes near-term financing risk and funds pipeline through 2029, but the stock will trade on clinical catalysts, watch for Phase 3 GT trial initiation in H2 2026 and data readouts for sutacimig (FVII deficiency) and HMB-002 (VWD) in late 2026/early 2027. No revenue or guidance to anchor valuation.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$26.30
T+0 close · May 21, 2026 · via day close
Latest settled
+103.76%
T+60 · $53.59
Vs SPY
+99.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 21 $26.30entry
  2. T+1 · 6mo ago −1.56%α −2.00% · $25.89
  3. T+5 · 6mo ago +8.37%α +6.52% · $28.50
  4. T+20 · 5mo ago +21.03%α +20.69% · $31.83
  5. T+60 · 3mo ago +103.76%α +99.46% · $53.59

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Hemab Therapeutics reported a Q1 2026 net loss of $22.7M ($23.98/share), widening from a $15.3M loss ($16.18/share) in Q1 2025, driven by higher R&D and G&A expenses. The company completed a $346.7M IPO in May 2026, extending its cash runway into 2029, and received FDA Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia. As a pre-revenue clinical-stage biotech, the earnings report itself is routine, but the IPO proceeds and regulatory milestone are the key value drivers.

Key Financial Metrics

EPS
−$23.98
Revenue
$0.00
est $0.00
Rating
in line

Key Facts

  • Net loss of $22.7M in Q1 2026 vs $15.3M in Q1 2025, driven by R&D expenses of $19.5M (up from $14.1M) and G&A of $4.2M (up from $2.5M).
  • Cash, cash equivalents, and marketable securities totaled $163.5M as of March 31, 2026; combined with $317.2M net IPO proceeds in May 2026, cash runway extends into 2029.
  • Completed upsized IPO of 19.26M shares at $18.00/share, raising $346.7M in gross proceeds.
  • FDA granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia in March 2026.
  • Phase 3 pivotal trial for sutacimig in GT expected to initiate in H2 2026; Phase 2 data for Factor VII deficiency and Phase 1/2 data for HMB-002 expected in late 2026 or early 2027.

Financial Impact

Net loss widened by $7.4M YoY; IPO added $346.7M gross proceeds; cash runway extended into 2029.

net losscash positionR&D expensesG&A expenses

Risk Factors

  • Pre-revenue clinical-stage company with no approved products; valuation depends entirely on pipeline success.
  • Phase 3 GT trial may fail to meet endpoints; regulatory path for Breakthrough Therapy designation is not guaranteed.
  • Cash burn rate is increasing as programs advance; additional financing may be needed beyond 2029.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3299177

Track record

19 reports on COAG

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
  5. Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
  6. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
  7. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
  8. Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
  9. May 21, 202625w ago Press Release Neutral 5/10 Viewing Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
  10. May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens Wed (10h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 21, 2026